FLUOROPHARMA MEDICAL, INC. - FORM 10-Q - EX-32.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - November 14, 2011

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - FLUOROPHARMA MEDICAL, INC.Financial_Report.xls
EX-10.1 - OFFICE USE AGREEMENT - FLUOROPHARMA MEDICAL, INC.ex10-1.htm
EX-10.3 - EMPLOYMENT AGREEMENT BETWEEN JOHAN "THIJS" SPOOR AND FLUOROPHARMA, INC. - FLUOROPHARMA MEDICAL, INC.ex10-3.htm
EX-10.2 - LEASE AGREEMENT BETWEEN HILLSIDE SQUARE LLC AND FLUOROPHARMA, INC. - FLUOROPHARMA MEDICAL, INC.ex10-2.htm
10-Q - FLUOROPHARMA 10Q SEPT 30 2011 - FLUOROPHARMA MEDICAL, INC.flph10qsept302011.htm
EX-31.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - FLUOROPHARMA MEDICAL, INC.ex31-1.htm
Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of FluoroPharma Medical, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Johan M. (Thijs) Spoor, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)  
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 

November  14, 2011
By:
/s/ Johan M. (Thijs) Spoor
   
Johan M. (Thijs) Spoor
Chief Executive Officer & Chief Financial Officer
(Principal Executive Officer and Principal Financial and Accounting Officer)
 

FLUOROPHARMA MEDICAL, INC. Reports